Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases. (Cancer Res Treat. 2008;40:36-38)
Abstract
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases. (Cancer Res Treat. 2008;40:36-38)
참고문헌 (15)
- Kumagai K., "Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan", Ann Oncol, 8, pp.107~9 (1997)
- Lok AS, "Chronic hepatitis B", Hepatology, 34, pp.1225~41 (2001)
- Tsutsumi Y., "Reactivation of hepatitis B virus with rituximab", Expert Opin Drug Saf, 4, pp.599~608 (2005)
- Dervite I., "Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab", N Engl J Med, 344, pp.68~9 (2001)
- Yamagata M., "Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab", Leuk Lymphoma, 48, pp.431~3 (2007)
- Sarrecchia C., "HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb", J Infect Chemother, 11, pp.189~91 (2005)
- Sera T., "Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab", Intern Med, 45, pp.721~4 (2006)
- Conjeevaram HS, "Occult hepatitis B virus infection: a hidden menace?", Hepatology, 34, pp.204~6 (2001)
- Brechot C., "Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”?", Hepatology, 34, pp.194~203 (2001)
- Kim SM, "Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea", J Infect, 54, pp.185~91 (2007)
- Yeo W., "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy", J Clin Oncol, 22, pp.927~34 (2004)
- Mason AL, "Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen", Hepatology, 27, pp.1736~42 (1998)
- Hu KQ, "Occult hepatitis B virus infection and its clinical implications", J Viral Hepat, 9, pp.243~57 (2002)
- Coiffier B., "Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis", Cancer Invest, 24, pp.548~52 (2006)
- Tur-Kaspa R., "Hepatitis B virus DNA contains a glucocorticoid-responsive element", Proc Natl Acad Sci USA, 83, pp.1627~31 (1986)